Castle Biosciences (CSTL) to Announce Quarterly Earnings on Thursday

Castle Biosciences (NASDAQ:CSTL) is expected to post its Q2 2026 results after the market closes on Thursday, July 30th. Analysts expect Castle Biosciences to post earnings of ($0.44) per share and revenue of $86.2360 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Thursday, July 30, 2026 at 4:30 PM ET.

Castle Biosciences (NASDAQ:CSTL) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.49). The business had revenue of $84.23 million for the quarter, compared to the consensus estimate of $79.23 million. Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. On average, analysts expect Castle Biosciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Castle Biosciences Trading Down 2.3%

CSTL opened at $23.89 on Wednesday. Castle Biosciences has a 1-year low of $14.59 and a 1-year high of $44.28. The stock has a market capitalization of $724.58 million, a PE ratio of -54.30 and a beta of 1.00. The company has a current ratio of 6.75, a quick ratio of 6.53 and a debt-to-equity ratio of 0.02. The firm has a 50-day moving average price of $22.39 and a two-hundred day moving average price of $26.71.

Wall Street Analysts Forecast Growth

CSTL has been the topic of several research analyst reports. Robert W. Baird decreased their price target on shares of Castle Biosciences from $44.00 to $43.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Wall Street Zen downgraded Castle Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Weiss Ratings lowered Castle Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Monday, June 1st. KeyCorp set a $35.00 target price on Castle Biosciences in a research note on Friday, May 29th. Finally, Canaccord Genuity Group dropped their target price on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a research report on Monday, April 20th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $42.43.

Insider Activity at Castle Biosciences

In other Castle Biosciences news, insider Derek J. Maetzold sold 3,622 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $24.29, for a total value of $87,978.38. Following the transaction, the insider directly owned 12,368 shares of the company’s stock, valued at approximately $300,418.72. This trade represents a 22.65% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Kristen M. Oelschlager sold 8,586 shares of Castle Biosciences stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $24.42, for a total transaction of $209,670.12. Following the sale, the chief operating officer directly owned 21,874 shares of the company’s stock, valued at $534,163.08. This represents a 28.19% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders have sold 45,189 shares of company stock valued at $1,014,561. 6.10% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CSTL. HRT Financial LP grew its stake in shares of Castle Biosciences by 0.9% during the fourth quarter. HRT Financial LP now owns 47,654 shares of the company’s stock worth $1,853,000 after purchasing an additional 415 shares during the period. Franklin Resources Inc. lifted its stake in Castle Biosciences by 0.5% in the third quarter. Franklin Resources Inc. now owns 99,787 shares of the company’s stock valued at $2,272,000 after buying an additional 540 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in Castle Biosciences by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock valued at $309,000 after buying an additional 655 shares during the period. Federated Hermes Inc. bought a new position in Castle Biosciences during the fourth quarter worth about $26,000. Finally, Kemnay Advisory Services Inc. bought a new position in Castle Biosciences during the fourth quarter worth about $35,000. Institutional investors and hedge funds own 92.60% of the company’s stock.

About Castle Biosciences

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.